Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib + CHOP in PTCL
NCT05963347Phase 2Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of golidocitinib in peripheral T-cell lymphoma (PTCL), sponsored by Henan Cancer Hospital. Started Aug 2023; status: recruiting.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05963347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05963347.